Various media have reported on studies addressing COVID-19 to be undertaken by several research centres in Catalonia. Among the groups involved is IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy. IRB Barcelona is one of eight research centres chosen by the European Commission to study new approaches to treat and diagnose COVID-19 and thus halt the spread of the virus.
Furthermore, NostrumBiodiscovery, cofounded by IRB Barcelona researcher Modesto Orozco, is collaborating with the Barcelona Supercomputing Center–Centro Nacional de Supercomputación (BSC-CNS) in another EC project. In this regard, the project aims to use cutting-edge biocomputation to support the intelligent design of drugs to treat COVID-19.
Link to: eldiario.es
Link to: El Confidencial
Link to: EFE
Link to: La Vanguardia
Link to: 20minutos
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).